Clinical Trial Evidence (RCT): CosmeRNA ARI in European Androgenetic Alopecia

Clinical Trial Evidence: CosmeRNA ARI in European Androgenetic Alopecia

A 2025 clinical research article published in Clinical and Experimental Dermatology and Therapies reports the results of a 6‑month, double‑blind, randomized, placebo‑controlled trial evaluating CosmeRNA ARI in adults with androgenetic alopecia in Germany.

In this study, participants were randomly assigned to receive either CosmeRNA ARI (an RNA‑interference‑based weekly topical tonic) or a placebo solution. Over six months, hair shedding and hair density were carefully measured, focusing on terminal hair density and the amount of shed hair compared with baseline and placebo.

The published results show that participants using CosmeRNA ARI experienced a significant reduction in hair shedding and a clear increase in terminal hair density by week 24, compared with the placebo group. Importantly, no serious safety concerns were observed during the 6‑month treatment period, confirming its favorable safety profile for long‑term use.

These findings highlight CosmeRNA ARI as a powerful, RNAi‑based solution for managing androgenetic alopecia in European men and women. It demonstrates real, measurable improvement in hair density and a reduction in hair loss, offering a convenient, once‑weekly regimen backed by rigorous clinical science. Individual results may vary, but the evidence supports CosmeRNA ARI as a leading option for advanced hair‑loss care.

Read the full research article:
Efficacy of CosmeRNA ARI in Improving Androgenetic Alopecia in Europeans: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial over 6 months

This content is provided for informational purposes only. The above text is an independent editorial overview and does not reproduce or substitute the original research article. It is not intended to diagnose, treat, cure, or prevent any medical condition.